Insulet Corporation announced positive clinical trial results for its next-generation Omnipod 6 automated insulin delivery system. The STRIVE pivotal trial showed strong glycemic outcomes and improved responsiveness to hyperglycemia, with the system delivering up to 50% more automated insulin while reducing the need for manual boluses across various age groups and diabetes types. The company also shared findings from the EVOLUTION 3 feasibility study, which focused on a fully closed-loop system specifically for type 2 diabetes that automatically adjusts insulin levels without requiring manual user settings. These developments align with Insulet's innovation strategy of reducing daily user effort while improving health outcomes.
Insulet CorporationPositive clinical trial results for next-gen Omnipod 6 and fully closed-loop system for type 2 diabetes.